Voruciclib is primarily investigated for its application in cancer therapy, particularly as a cyclin-dependent kinase (CDK) inhibitor. It targets specific CDKs involved in cell cycle regulation, making it a potential treatment for various cancers, including hematologic malignancies and solid tumors. By inhibiting these kinases, Voruciclib can disrupt the proliferation of cancer cells, leading to their death. It is often studied in combination with other anticancer agents to enhance therapeutic efficacy, especially in cases where resistance to standard treatments has developed. Clinical trials are ongoing to evaluate its safety, tolerability, and effectiveness in patients with advanced or refractory cancers.